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Neuroleptic malignant syndrome (NMS) represents a cluster of 
adverse effects of antipsychotic medications including: hypertonicity, 
autonomic instability, fever, and cognitive disturbance.1 It is a 
rare but potentially life-threatening complication of neuroleptic 
(antipsychotic) drug therapy, with a mortality rate of 5 - 25%2 
and an incidence of 0.01 - 0.02% in adults.3 The incidence rates in 
children and adolescents are uncertain. Precipitation of NMS may 
occur within hours of the first dose or after a period of maintenance 
treatment if there has been an increase in dose. All antipsychotics, 
including the newer atypical ones, have been associated with the 
development of NMS. Morbidity and mortality are predominantly 
the result of cardiopulmonary and renal complications.4
Presentations of NMS vary, and many diagnostic criteria have 
been proposed.2,3 The DSM-1V-TR diagnostic criteria3 require both 
core symptoms (fever, rigidity) and 2 or more additional symptoms 
(diaphoresis, dysphagia, tremor, incontinence, altered mental status, 
mutism, tachycardia, labile blood pressure, leukocytosis and evidence 
of muscle damage, e.g. raised creatine phosphokinase CK level).3 
Therefore, a raised CK level is not a mandatory diagnostic sign but 
one of many possible additional features. Diagnostic criteria used 
in adults are applied to children and adolescents and, with a few 
exceptions, NMS presents similarly in children and in adults.1
Table I presents data from 4 cases of probable NMS seen between 
February 2009 and March 2010; all were eventually referred to, and 
managed at, a rehabilitation unit for adolescents with psychosis at 
Lentegeur Hospital. They represent 3.6% of admissions over that time. 
While reference is made to a diagnosis of NMS, it is acknowledged that 
the evidence is circumstantial and, while fairly strong, is nevertheless 
presumptive.
Discussion
The cases suggest that male gender and polypharmacy (including 
the use of 2 or more antipsychotics), a past history of EPSE/NMS 
and agitation are important possible risk factors for NMS. Although 
intellectual disability and affective disorders are considered to increase 
vulnerability to NMS, these cases occurred in adolescents with normal 
intellectual functioning and without an overwhelming association 
with affective disorder. Other features include large variations in 
CK levels and a favourable outcome. Other key risk factors for 
NMS include: use of physical restraint to control psychomotor 
agitation, recent commencement of an antipsychotic regime, use of 
intramuscular antipsychotics, and excessive psychomotor agitation 
resulting in higher levels of dehydration.5 This raises the dilemma 
about appropriate, yet safe, use of antipsychotics in youths who 
need antipsychotics to control their behaviour, in particular those 
receiving high doses in short time periods.5 Zuclopenthixol acetate 
(clopixol acuphase) is a common denominator in 3 cases (2, 3 and 
4), and oral haloperidol was co-prescribed in 3 cases (1, 2 and 4). 
The Cochrane systematic review database found limited efficacy 
data for claims that zuclopenthixol acetate would rapidly calm or 
sedate aggressive patients with schizophrenia.6 Therefore, the use of 
zuclopenthixol acetate in neuroleptic-naïve adolescents with a first-
presentation psychotic illness, and for the specific purpose of rapid 
tranquillisation, must be carefully considered.
Body temperature recording in this series was often taken 
haphazardly and in difficult circumstances such as marked agitation 
and restlessness, when it is unsafe to use the oral method. Temperature 
readings were obtained from the axilla. In one case the temperature 
was never recorded, one patient had no pyrexia, and 2 patients 
showed only a mild elevation. A core feature of NMS is pyrexia; 
therefore it could be argued that at least 2 patients did not conform to 
a ‘true’ NMS. However, the additional signs and symptoms noted in 
all the subjects were consistent with a probable diagnosis of NMS.
Important differential diagnoses in adolescents with probable 
NMS are malignant hyperthermia, heat stroke, anticholinergic 
delirium, serotonin syndrome, central nervous system infection and 
neuroleptic-induced dystonia. The latter occurs within 7 days of 
initiating drug treatment or following a rapid increase in the dose 
and is an involuntary contraction of muscle groups forcing certain 
parts of the body into abnormal, sometimes painful, postures. It is not 
associated with fluctuations in blood pressure, pyrexia, tachycardia or 
any other additional signs or symptoms seen with NMS.
Silva et al.1 emphasise that, in children and adolescents, NMS 
presents in a form and course similar to adults. A fatal outcome is 
associated with age <12 years, although the number of fatal outcomes Corresponding author: T Henderson (thenders@pgwc.gov.za)
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Background. Neuroleptic malignant syndrome (NMS) is a rare side-
effect of neuroleptic medication. Most NMS reports have been on 
adults, and the incidence in children and adolescents is unknown.
Objective. This report reviews cases of NMS to highlight possible 
risk factors for the development of NMS in adolescents.
Method. Four cases of probable NMS in adolescents diagnosed 
in the Western Cape between February 2009 and March 2010 are 
presented.
Results. Risk factors in the development of the syndrome in 
adolescents in the Western Cape may be male gender, polypharmacy, 
the use of zuclopenthixol acetate (clopixol acuphase), a previous 
history of extra-pyramidal side-effects or NMS, and a history of 
substance misuse  – in particular methamphetamine.
Conclusion. Caution must be applied in the apparent overuse of 
intramuscular antipsychotics, and especially zuclopenthixol acetate 
(clopixol acuphase), in neuroleptic-naïve and agitated psychotic 
adolescents where the short-term use of benzodiazepines is more 
appropriate.
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has dropped sharply in all age groups in recent years. A milder course 
of NMS associated with atypical antipsychotics, a greater resilience 
in children, earlier detection, prompt antipsychotic discontinuation 
and more aggressive management of NMS are additional moderating 
factors.3 The latency period in these 4 cases refers to the time elapsed 
between the administration of an intramuscular antipsychotic and 
the diagnosis of possible NMS. Signs of NMS develop within 24 
hours in 16% of patients initiating antipsychotic medication, 66% by 
1 week and 90% within 30 days, and NMS is less likely to occur after 
30 days.9 Treatment of NMS includes referral to a medical unit, fever 
reduction, intravenous rehydration, dantrolene and bromocriptine, 
and sedation with benzodiazepines. Electroconvulsive therapy is 
an effective treatment option both for the NMS and the underlying 
psychiatric illness.3 After resolution of NMS and normalisation of CK 
level, a 2-week waiting period is recommended before re-exposure to 
antipsychotics.
In 2 of the 4 cases, crystal methamphetamine, a street drug 
manufactured from ephedrine or pseudo-ephedrine that is smoked 
or injected and popularly known as ‘tik’ in the Western Cape, was 
one of the substances used prior to illness. Its use has accelerated 
Table I. Patient data related to 4 probable cases of NMS 
Case 1 Case 2 Case 3 Case 4
Age, gender 17, male 16, male 16, male 16, male
Diagnosis Schizophrenia Bipolar mood disorder Schizophreniform 
disorder
Schizophrenia
First presentation No, known schizophrenic, 
previous EPSE, treated on 
clozapine
Yes Yes No, known  schizophrenic, 
previous diagnosis of 
NMS
Intellectual functioning Normal Normal Normal Normal






Presenting history Psychotic, aggressive, 
disruptive
Psychotic Psychotic Psychotic, restlessness
Agitation prior to NMS Yes Yes No Yes
Medication (incl. route of 
administration and dose)
Haloperidol 2.5 mg 20h00, 
flupentixol 10 mg IMI × 2
Zuclopenthixol acetate  
25 mg, haloperidol 1.5 mg 
twice daily, diazepam  
20 mg thrice daily
Zuclopenthixol acetate  
50 mg IMI, risperidone 
0.5 mg twice daily
Zuclopenthixol acetate  
50 mg IMI × 2, 
haloperidol 5 mg twice 
daily, lorazepam 4 mg 
thrice daily
Latency period 5 days 11 days 1 day 4 days
Highest recorded 
temperature
36.70C 37.50C 37.40C 37.40C
Rigidity Present Present Present Present
BP fluctuation No No No Not recorded
Tachycardia 120 bpm 120 bpm 126 bpm Not recorded
Tremor NN NN No No
Dystonia Yes NN No No
Diaphoresis NN Yes No No
Incontinence NN NN Yes No
Dysphagia NN NN NN Yes
WCC 15.9 cells/mm3 NN 7.86 cells/mm3 3.86 cells/mm3
CK (highest) 5 307 IU/l 783 IU/l 10 000 IU/l 1 173 IU/l
Na, liver enzymes, EEG, 
CT scan, MRI, CSF
Negative Negative Negative Negative
Treatment Antipsychotics were 
stopped. Treated with 
diazepam.
Antipsychotics were 
stopped. Treated with 
lorazepam. 
Antipsychotics stopped. 




Outcome Full recovery from NMS. 
Discharged on clozapine.
Full recovery from NMS. 
Discharged on quetiapine.
Full recovery from NMS. 
Discharged on clozapine.
Full recovery from 
NMS. Discharged on 
risperidone.
NN = nil noted; EPSE = extra-pyramidal side-effects.
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in the Western Cape since 2003, particularly among the youth. This 
observation suggests a possible relationship between substance abuse 
and the development of NMS. Methamphetamine causes the release 
of dopamine and noradrenaline (and, to a lesser extent, serotonin) 
into the synaptic cleft and inhibits their reuptake. This creates very 
high intrasynaptic dopamine concentrations that probably accelerate 
or exacerbate the psychotic process. Chronic use of stimulants such 
as methamphetamine or cocaine may predispose the individual 
to NMS.11 A hypothetical mechanism is that the initial dopamine 
stimulation induced by methamphetamine is followed by a depletion 
of neuronal dopamine reserves with continuing use of the agent. 
The resulting dopamine deficiency would be aggravated by the 
therapeutic administration of antipsychotics that further compound 
the hypodopaminergic state by their blockade of post-synaptic 
receptors. These events establish a setting of reduced dopamine 
activity, which is probably the aetiological basis for NMS.
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